Clinical Trials Logo

Neoplasm Metastasis clinical trials

View clinical trials related to Neoplasm Metastasis.

Filter by:

NCT ID: NCT05588297 Not yet recruiting - Clinical trials for Colorectal Cancer Liver Metastases

Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver Metastases

Start date: October 2022
Phase: Phase 2
Study type: Interventional

This prospective, single-arm study aims to investigate the safety and efficacy of Nivolumab plus bevacizumab and chemotherapy as neoadjuvant treatment in pMMR/MSS Colorectal cancer liver metastases patients

NCT ID: NCT05578274 Not yet recruiting - Neoplasms Clinical Trials

Abscopal Effect From Low-dose Radiotherapy in Metastatic Cancer Combined With Stereotactic Body Radiotherapy

Start date: June 2024
Phase: N/A
Study type: Interventional

Stereotactic body radiotherapy (SBRT) has been known to enhance the abscopal effect by up to 40% when delivered with immune checkpoint inhibitors (ICIs). Recently, preclinical and clinical studies demonstrate that metastatic lesions treated with non-cytotoxic low-dose radiotherapy (LDRT) significantly were reduced in the condition where SBRT and ICIs were administered together. Given that ICIs are highly expensive and some tumors are beyond the indications of ICIs, novel approaches are required to boost the abscopal effect in the absence of ICIs. Therefore, the investigators design a multicenter, randomized clinical trial that investigates the efficacy and safety of LDRT combined with SBRT in metastatic cancer patients. The primary endpoint is a lesion-specific response of LDRT lesions (i.e., abscopal effect) evaluated three months after radiotherapy. Subjects will be randomly allocated into two groups (1:1) with the stratification by planning target volume and previous use of ICIs: control group (SBRT in three fractions) or experimental group (SBRT + LDRT in three factions). Unless patients agree with randomization, subjects will participate in a prospective cohort study.

NCT ID: NCT05577052 Not yet recruiting - NSCLC Clinical Trials

SBRT Versus Conventional Fractionated Radiotherapy for Vertebral Metastases

Start date: October 30, 2022
Phase: N/A
Study type: Interventional

Vertebral metastases are events that affect the quality of life of tumor patients, and are often accompanied by severe pain at the site of metastasis and even by the risk of compression fracture. For vertebral metastases who are not yet at risk of vertebral instability fracture, a moderate dose (30Gy/10F) external radiation therapy is the most widely used treatment technique. Previous studies have shown that 60-80% of patients could achieve pain relief with moderate doses of radiation therapy, with median pain control duration of approximately 4 months. Stereotactic Radiation Therapy (SBRT) is currently the most advanced radiation therapy technique. This project proposes to treat vertebral metastases from non-small cell lung cancer using SBRT technology on the True Beam radiotherapy system to compare its efficacy with conventional external irradiation technology in terms of pain relief as well as local control.

NCT ID: NCT05524155 Not yet recruiting - Colorectal Cancer Clinical Trials

Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis

Start date: September 2022
Phase: Phase 2
Study type: Interventional

To evaluate the safety and efficacy of sintilimab combined with regorafenib and HAIC in patients with colorectal liver metastasis who failed second-line therapy

NCT ID: NCT05495802 Not yet recruiting - Bone Metastases Clinical Trials

Regional Database for Collecting Clinical-biological and Imaging Data "Secondary Bone Oncology and Bone Localizations of Hematologic Diseases"

OOSLOH
Start date: December 2022
Phase:
Study type: Observational

Improving the effectiveness of cancer treatments makes it possible to lengthen patient survival. It is therefore important to ensure that the quality of life is also maintained by reducing pain and handicap. Some cancers tend to spread to the bone. The bone locations of cancer can weaken the bone and lead to complications such as fractures, pain, or compression of neurological structures. To avoid such complications, weekly multidisciplinary meetings (MM) bring together specialists (oncologists, rheumatologists, cancer surgeons, radiologists, radiotherapists, etc.) to discuss the files of patients with bone lesions from cancer. They offer specific treatments adapted to each patient to treat or reduce the risk of complications. The OOSLOH study aims to collect clinical, biological, and imaging data from patients for whom a discussion took place in bone dedicated MM. Based on these data, epidemiological studies could be carried out to better understand the clinical factors leading cancer to colonize bone. But also to determine the factors making it possible to prevent or better treat bone complications and improve the quality of life of patients. This study does not require any examinations or additional visits to the patient

NCT ID: NCT05480189 Not yet recruiting - Clinical trials for Histologically Confirmed Breast Cancer ,Diagnosis of Bone Metastasis

Effect of Zoledronic Acid Treatment on Bone-related Events in Breast Cancer Patients With Bone Metastases: a Prospective, Multicenter, Real-world Study

Start date: August 30, 2022
Phase:
Study type: Observational

non-intervention、real world study; Effect of timing and regular treatment of zoledronic acid on the incidence of SREs in breast cancer patients

NCT ID: NCT05466812 Not yet recruiting - Bone Metastases Clinical Trials

Efficacy of Sr-89 for Differentiated Thyroid Cancer With Bone Metastases

Start date: July 13, 2022
Phase: Phase 4
Study type: Interventional

Using sensitive markers (such as thyroglobulin, etc) to evaluate the efficacy of strontium-89 chloride (Sr-89) in differentiated thyroid cancer with bone metastases with an aim to breaking out of its palliation effect for bone pain.

NCT ID: NCT05455216 Not yet recruiting - Metastatic Cancer Clinical Trials

Peer Caregiver Navigation for Family Caregivers in Oncology

Start date: July 2022
Phase: N/A
Study type: Interventional

This clinical trial assesses the feasibility and acceptability of the psychosocial intervention peer caregiver navigation (PCN) in an outpatient oncology setting. PCN is a peer mentoring service designed to help family caregivers navigate and mitigate the distress of caregiving by enhancing and promoting the emotional and behavioral coping efforts of the caregiver.

NCT ID: NCT05441254 Not yet recruiting - Clinical trials for Stage IV Gastric Cancer With Metastasis

Camrelizumab Combined With Intraperitoneal Infusion of Nab-paclitaxel, Intravenous Chemotherapy and S-1 in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis:Single-arm, Prospective Clinical Study

Start date: July 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study was to evaluate the efficacy of camrelizumab combined with nab-paclitaxel intraperitoneal infusion, intravenous chemotherapy and S-1 in the treatment of advanced gastric cancer with peritoneal metastasis, so as to preliminarily explore the feasibility of the three-drug combination regimen in patients with gastric cancer with peritoneal metastasis and safety, and strive to maximize the benefits of different groups of people.

NCT ID: NCT05361954 Not yet recruiting - Cancer Clinical Trials

Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors

Start date: August 2023
Phase: Phase 1
Study type: Interventional

This is a Phase 1b study to assess the safety and tolerability of STI-1386, an oncolytic virus, in subjects with relapsed and refractory solid tumors (RRSTs).